Bright.md announced a merger with Vancouver-based MyCare MedTech this week for an innovative customer deployment, setting foot into the global marketplace.
San Francisco based Verge Genomics, the Neuroscience based drug discovery company launched in 2015, has raised $32 million in early venture capital financing to bring its AI-generated compounds against Parkinson’s disease and amyotrophic lateral sclerosis (ALS) to clinics within the next three years.
The U.S. Food and Drug Administration approved the first autonomous artificial intelligence diagnostic system, IDx-DR and the University of Iowa Healthcare has become the first healthcare organization to implement it.
A recent survey from Intel revealed that health system decision-makers have considered artificial intelligence as a new element of life. Still, many people are anxious as to whether it could provide safe care.
Babylon’s system initiates with a conversation and continues into an AI-assisted telemedicine visit. Apart from physician’s conversation with the patient, the system generates visit notes for the physicians. Even the patient’s facial expressions were analyzed and reported to the doctor. Babylon is working on the Alexa app, which would be released by the end of August.
India, Bengaluru based SigTuple, a startup focusing on Artificial Intelligence for Healthcare has raised $19 million in their series B funding. The investment was led by IDG Ventures, pi Ventures Partners along with Accel, Axilor Ventures, VH Capital, Endiya Partners and Flipkart’s executive chairman Binny Bansal. The startup has also bagged venture debt from Trifecta Capital in this round. In an earlier investment round, the company raised $6.5 million from various investors.
Medtronic, a medical technology company, and AI-powered personalized nutrition platform Nutrino, have entered into a partnership. The FoodPrint Report technology of Nutrino is slated to be integrated into the iPro2myLog app of Medtronic, a platform which offers continuous glucose monitor enabling users to gain critical insights into their glucose levels.
The Food and Drug Administration (FDA) has granted approval for a request made by DreaMed regarding their artificial intelligence-enabled diabetic software, which is exclusively meant for the providers, who are managing Type 1 diabetes patients.
The startup also revealed its new research on Textray, which the company claims to be the “most comprehensive Artificial Intelligent research till now.” This is all working towards developing their new product which is currently capable of identifying 40 clinical findings as a result of training via 2 million images.
Mark Michalski, MD, executive director of the Massachusetts General Hospital and Brigham and Women's Hospital Center for Clinical Data Science stated that the anticipation regarding AI is due to three key factors: the increasing contribution of digital data that can be created, the creation of algorithms that make artificial neural networks and "GPU" chip architecture (graphics processing unit), developed by NVIDIA.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.